Tramadol (Ultram)
tramadol hydrochloride
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderate to moderately severe pain (immediate-release) | Adults ≥17 years | Monotherapy or adjunct; for pain severe enough to require opioid-level analgesia | FDA Approved |
| Chronic pain requiring around-the-clock analgesia (extended-release) | Adults ≥18 years | Around-the-clock pain management; not for as-needed use | FDA Approved |
Tramadol occupies a unique position among analgesics as a centrally acting agent with dual mechanisms: weak mu-opioid receptor agonism (primarily through its active metabolite M1) and inhibition of serotonin and norepinephrine reuptake. This dual pharmacology provides analgesia that is only partially reversed by naloxone and carries both opioid-type and SNRI-type risk profiles. Its classification as a Schedule IV controlled substance reflects its lower abuse potential relative to traditional opioids, though dependence and misuse remain clinically significant concerns. Tramadol is positioned for moderate pain when non-opioid analgesics are insufficient, but it should not be considered a “safe” alternative to stronger opioids given its unique toxicity profile including seizure and serotonin syndrome risk.
Premature ejaculation: Tramadol’s serotonin reuptake inhibition can delay ejaculation; systematic reviews support efficacy, though recent guidelines advise caution due to habituation risk. Evidence quality: Moderate.
Restless legs syndrome (refractory): Used when dopamine agonists and gabapentinoids are inadequate or have caused augmentation. Evidence quality: Low.
Neuropathic pain: The SNRI component provides potential benefit in neuropathic pain conditions; some guidelines include tramadol as a second- or third-line option. Evidence quality: Moderate.
Dosing
Immediate-Release Tablets (50 mg)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate pain — standard adult, opioid-naive | 25 mg/day Titrate by 25 mg q3 days | 50–100 mg q4–6h | 400 mg/day | Slow titration reduces nausea and dizziness; may take with or without food Reach 25 mg QID by day 10, then increase total daily dose by 50 mg q3 days |
| Moderate pain — rapid titration needed | 50 mg q6h | 50–100 mg q4–6h | 400 mg/day | Higher initial GI and CNS side effects; reserve for situations where slower titration is impractical |
| Elderly patient (≥65 years, especially >75 years) | 25 mg/day | 50–100 mg q4–6h | 300 mg/day If >75 years | Elderly >75: Cmax elevated (208 vs 162 ng/mL), t½ prolonged (~7 h); 30% GI treatment-limiting events in >75 yr group Cautious, slow titration mandatory |
| Severe renal impairment (CrCl <30 mL/min) | 50 mg q12h | 50–100 mg q12h | 200 mg/day | Not substantially removed by dialysis (<7% in 4 h); administer regular dose on dialysis days |
| Hepatic impairment (cirrhosis) | 50 mg q12h | 50 mg q12h | 100 mg/day | AUC and half-life are increased in advanced cirrhosis; metabolism of both tramadol and M1 is reduced |
Extended-Release Tablets/Capsules (100, 200, 300 mg)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic pain requiring around-the-clock therapy | 100 mg once daily | 100–300 mg once daily Titrate by 100 mg every 5 days | 300 mg/day | Swallow whole; never crush, split, or chew (risk of fatal dose dump); discontinue other around-the-clock opioids when initiating Not for as-needed or acute pain |
| Switching from IR to ER — calculate total daily IR dose | Nearest lower 100 mg increment | Titrate to effect | 300 mg/day | Not all patients can be successfully switched; some may need additional IR breakthrough doses during transition |
| Severe renal or hepatic impairment | ER formulations are not recommended — insufficient dosing flexibility for safe use in these populations | |||
The most common reason for tramadol discontinuation is GI and CNS adverse effects during the initial titration period. Starting at 25 mg/day and increasing by 25 mg every 3 days to 25 mg four times daily significantly reduces the incidence of nausea and dizziness compared to starting at full dose. Once patients tolerate 100 mg/day (25 mg QID), the total daily dose can be increased by 50 mg every 3 days as needed. This approach trades speed for tolerability, and three to five studies confirm that adverse event rates are highest during the first week and decline with continued treatment.
Pharmacology
Mechanism of Action
Tramadol is a centrally acting synthetic analgesic with a dual mechanism that distinguishes it from traditional opioids. The (+)-enantiomer of tramadol and its primary active metabolite O-desmethyltramadol (M1) bind to mu-opioid receptors, with M1 demonstrating approximately 200-fold greater mu-receptor affinity than the parent compound and up to 6-fold greater analgesic potency in animal models. In parallel, (+)-tramadol inhibits serotonin reuptake while (-)-tramadol inhibits norepinephrine reuptake, enhancing descending inhibitory pain pathways in the spinal cord. This complementary activity means tramadol-induced analgesia is only partially reversed by naloxone. Unlike morphine, tramadol does not cause histamine release and has no clinically significant effects on heart rate, left-ventricular function, or cardiac index at therapeutic doses.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~75% (single 100 mg dose), increasing to >90% with multiple doses; Tmax ~2 h (parent), ~3 h (M1); food does not significantly affect absorption | Rapid onset (~1 h) with peak analgesia at 2–3 h; can be taken without regard to meals; first-pass metabolism accounts for 20–30% of dose |
| Distribution | Vd 2.6–2.9 L/kg; protein binding ~20% (concentration-independent); crosses placenta (umbilical:maternal ratio ~0.83) | Extensive tissue distribution; low protein binding means interactions from displacement are unlikely; crosses into breast milk |
| Metabolism | Hepatic: CYP2D6 → O-desmethyltramadol (M1, active); CYP3A4/CYP2B6 → N-desmethyltramadol (M2, inactive); phase II conjugation (glucuronidation, sulfation) | CYP2D6 polymorphism critically affects efficacy: poor metabolizers (~7%) have ~20% higher tramadol and ~40% lower M1 levels, diminishing analgesia; ultrarapid metabolizers have excess M1 and toxicity risk — FDA contraindicates use in ultrarapid metabolizers |
| Elimination | t½ ~6 h (tramadol), ~7 h (M1); ~90% renal excretion (30% unchanged, 60% metabolites); <7% removed by 4 h dialysis | Renal impairment extends exposure of both parent and M1; half-life prolongs from 6 to 7 hours in elderly >75 yr; dose reduction required in CrCl <30 mL/min |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness/Vertigo | 26–33% | Most common CNS effect; dose-related; highest during initial titration and improves with continued use |
| Nausea | 24–40% | Cumulative incidence increases over time; slow titration starting at 25 mg/day substantially reduces early nausea |
| Constipation | 24–46% | Does not habituate; requires proactive bowel regimen throughout therapy; 10% discontinuation rate in elderly >75 |
| Headache | 18–32% | Cumulative incidence; usually mild; may be related to serotonergic activity |
| Somnolence | 16–25% | Additive with CNS depressants and alcohol; advise caution with driving and hazardous activities |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Vomiting | 9–17% | Peaks during first week of therapy; anti-emetic co-prescription may help during titration |
| Pruritus | 8–11% | Opioid-mediated rather than histamine-mediated; does not respond well to antihistamines |
| CNS stimulation (nervousness, anxiety, agitation) | 7–14% | Related to serotonergic and noradrenergic reuptake inhibition; may be misinterpreted as anxiety disorder |
| Asthenia/Fatigue | 6–12% | Usually improves after the first 1–2 weeks of stable dosing |
| Sweating/Diaphoresis | 6–9% | Opioid class effect; can be distressing but rarely treatment-limiting |
| Dyspepsia | 5–13% | May improve if taken with food, though PK unaffected by meals |
| Dry mouth | 5–10% | Anticholinergic-like effect; encourage oral hydration |
| Diarrhea | 5–10% | Less common than constipation; may alternate with constipation in some patients |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Seizures | ~0.5% at therapeutic doses | Any time; risk increases with dose >400 mg/day, concurrent serotonergic drugs, epilepsy history, or withdrawal | Discontinue tramadol; benzodiazepine for acute seizure; evaluate and manage precipitating factors; do not rechallenge |
| Serotonin syndrome | Rare | Within hours to days; typically with concurrent serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans) | Discontinue all serotonergic agents immediately; supportive care; cyproheptadine in moderate-to-severe cases; ICU if hyperthermic |
| Respiratory depression | Rare at therapeutic doses | Within hours of dosing; risk highest at initiation, dose increases, or with concurrent CNS depressants/benzodiazepines | Naloxone (partial reversal only — may precipitate seizures); ventilatory support; reduce dose or discontinue |
| Anaphylactoid reactions | Very rare | Usually first dose or early therapy | Epinephrine, airway management; permanent discontinuation |
| Adrenal insufficiency | Very rare | After ≥1 month of use; nonspecific presentation (fatigue, weakness, nausea, hypotension) | Diagnostic cortisol testing; taper and discontinue tramadol; physiologic corticosteroid replacement until recovery |
| Neonatal opioid withdrawal syndrome | Expected with prolonged maternal use | Within hours to days of delivery | Neonatal monitoring and supportive care; do not abruptly discontinue in pregnant patients — taper; neonatology consultation |
| Hypoglycemia | Rare | Any time; more common in diabetic patients | Monitor blood glucose; treat symptomatically; consider dose reduction or alternative analgesic |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Nausea/Vomiting | ~9% | Most common early discontinuation reason; peaks in first 7 days; reduced by slow titration |
| Dizziness | ~6% | Dose-related; worse in elderly and with concurrent CNS depressants |
| Constipation | ~5% | Does not habituate; proactive bowel management essential; 10% in elderly >75 |
| Headache/Somnolence | ~3% | Usually improves with continued therapy at stable doses |
The majority of tramadol discontinuations occur during the initial titration period. Clinical trial data consistently show that adverse event rates are highest in the first 7 days and decline substantially by day 30. The recommended slow-titration approach (starting at 25 mg/day, increasing by 25 mg every 3 days) dramatically improves tolerability. For patients who experience significant nausea during titration, a short course of an anti-emetic such as ondansetron or metoclopramide can bridge the tolerability gap. Importantly, do not use 5-HT3 antagonists routinely as they may theoretically reduce tramadol’s serotonergic analgesic component.
Drug Interactions
Tramadol’s dual mechanism creates two distinct interaction axes: opioid-type interactions (respiratory depression, sedation) and serotonergic interactions (serotonin syndrome, seizures). Its metabolism through CYP2D6 and CYP3A4 adds a pharmacokinetic dimension. The net clinical effect of CYP2D6 inhibition is complex — increased parent drug (more serotonergic risk, seizure risk) but decreased M1 (less opioid effect, potentially reduced analgesia).
Monitoring
-
Pain Assessment
Each visit
Routine Validated pain scale at initiation and each follow-up. Re-evaluate benefit vs risk at least every 3 months for chronic use. Document functional outcomes, not just pain scores. -
Respiratory Status
At initiation & dose changes
Routine Monitor respiratory rate, oxygen saturation, and sedation level, especially during the first 24–72 hours of therapy or dose increases. Highest risk with concurrent benzodiazepines or CNS depressants. -
Bowel Function
Each visit
Routine Proactively assess constipation at every visit. Initiate a bowel regimen (stimulant laxative ± stool softener) at the start of therapy; constipation does not resolve with habituation. -
Signs of Misuse / Addiction
Each visit
Routine Screen for aberrant drug-related behaviors. Check prescription drug monitoring programs (PDMP) before prescribing and periodically. Consider urine drug testing. Risk assessment tools (e.g., ORT) at baseline. -
Serotonin Syndrome Signs
At each visit if on serotonergic drugs
Trigger-based Assess for agitation, hyperthermia, tachycardia, clonus, hyperreflexia, diaphoresis, and tremor. Risk is highest when tramadol is combined with SSRIs, SNRIs, TCAs, MAOIs, or triptans. -
Seizure Risk
At each visit
Trigger-based Assess seizure risk factors: epilepsy history, concurrent seizure-threshold-lowering drugs (antipsychotics, TCAs), dose exceeding 400 mg/day, alcohol/drug withdrawal. Counsel patients on seizure warning signs. -
Renal & Hepatic Function
Baseline; annually for chronic use
Routine Dose adjustment required for CrCl <30 and hepatic cirrhosis. Monitor creatinine and LFTs at baseline and periodically in chronic users. -
Blood Glucose
If symptoms arise
Trigger-based Tramadol can cause hypoglycemia. Monitor glucose in diabetic patients or if symptoms of hypoglycemia develop (tremor, sweating, confusion, hunger).
Contraindications & Cautions
Absolute Contraindications
- Significant respiratory depression — tramadol can further suppress respiratory drive, especially with concurrent CNS depressants
- Acute or severe bronchial asthma in unmonitored settings or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Concurrent or recent (within 14 days) use of MAO inhibitors — risk of serotonin syndrome and seizures
- Hypersensitivity to tramadol, opioids, or any component
- Children <12 years of age — FDA contraindication due to risk of fatal respiratory depression
- Post-tonsillectomy/adenoidectomy pain management in children <18 years
- CYP2D6 ultrarapid metabolizers — excess M1 formation leading to life-threatening respiratory depression (FDA contraindication)
Relative Contraindications (Specialist Input Recommended)
- History of seizure disorder — tramadol lowers seizure threshold; risk further increased with concurrent seizure-threshold-lowering medications
- Concurrent serotonergic medications (SSRIs, SNRIs, TCAs, triptans) — requires careful risk-benefit assessment and close monitoring for serotonin syndrome
- History of substance use disorder — tramadol has abuse potential (Schedule IV); increased risk of addiction and diversion
- Severe hepatic impairment — ER formulations contraindicated; IR requires major dose reduction
- Severe renal impairment (CrCl <30) — ER formulations not recommended; IR at reduced dose only
Use with Caution
- Elderly patients (>75 years) — prolonged half-life, elevated Cmax, higher discontinuation rates; max 300 mg/day
- Head injury or increased intracranial pressure — tramadol may obscure neurological assessment and elevate ICP via CO2 retention
- CYP2D6 poor metabolizers (~7%) — reduced M1 formation may diminish analgesic response; higher parent tramadol levels increase serotonergic and seizure risks
- Concurrent alcohol use — additive CNS depression; risk of fatal respiratory failure
- Hypothyroidism, adrenal insufficiency, prostatic hypertrophy — standard opioid precautions apply
- Biliary tract disease — opioids can cause biliary spasm; use with caution
Addiction, abuse, and misuse: Tramadol exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk before prescribing and monitor regularly for development of these behaviors.
Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation or dose escalation.
Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.
Interactions with CNS depressants: Concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concurrent prescribing for patients without adequate alternatives.
CYP2D6 ultrarapid metabolism in children: Life-threatening respiratory depression and death have occurred in children who received tramadol and were ultrarapid metabolizers of CYP2D6. Tramadol is contraindicated in children <12 years and for post-tonsillectomy/adenoidectomy pain in children <18 years.
Patient Counselling
Purpose of Therapy
Tramadol is a prescription pain medication that works in two ways: it activates pain-relief pathways in the brain (similar to mild opioids) and increases levels of natural chemicals (serotonin and norepinephrine) that help your body manage pain signals. It is used for moderate to moderately severe pain when other non-opioid painkillers have not been sufficient. Although it is less potent than stronger opioids like morphine, tramadol still carries risks of dependence, side effects, and potentially dangerous interactions with other medications.
How to Take
Take tramadol exactly as prescribed. For immediate-release tablets, your prescriber will likely start you on a low dose and gradually increase it over several days to reduce side effects. For extended-release tablets or capsules, take them once daily at the same time each day; swallow them whole — never crush, break, or chew them, as this can release a dangerous amount of medication at once. You can take tramadol with or without food. Store securely away from children and anyone who might misuse it.
Sources
- Tramadol Hydrochloride Tablets — FDA-Approved Prescribing Information (Ultram). dailymed.nlm.nih.gov Primary reference for IR dosing, pharmacokinetics (Table 1), adverse reaction incidences, drug interactions, and contraindications.
- Ultram ER (tramadol hydrochloride) Extended-Release Tablets — FDA-Approved Prescribing Information. accessdata.fda.gov Source for ER-specific dosing, titration schedule, ER pharmacokinetics, and clinical trial results in osteoarthritis pain.
- Tramadol Hydrochloride Extended-Release Capsules — FDA-Approved Prescribing Information. accessdata.fda.gov Reference for ER capsule formulation, adverse event rates by dose from pooled double-blind studies (Table 1), and renal/hepatic impairment data.
- Langley PC, Patkar AD, Boswell KA, et al. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin. 2010;26(1):239–251. doi:10.1185/03007990903407646 Systematic review of 15 clinical studies (n=6,142) comparing adverse event rates across tramadol formulations in chronic osteoarthritis pain.
- Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27(3):772–778. Pivotal RCT demonstrating tramadol efficacy in chronic low back pain with documentation of dose-related adverse events and discontinuation rates.
- Motov S, Drapkin J, Butt M, et al. Analgesic administration for patients with renal colic in the emergency department before and after implementation of an opioid reduction initiative. West J Emerg Med. 2018;19(6):1028–1035. doi:10.5811/westjem.2018.9.38875 Evidence supporting tramadol as part of opioid-sparing strategies in emergency department pain management.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95. doi:10.15585/mmwr.rr7103a1 Current CDC guideline on opioid prescribing for pain; provides framework for risk assessment, dosing limits, and monitoring requirements applicable to tramadol.
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372 Classifies tramadol among opioids requiring cautious use in older adults due to falls, fractures, and CNS depression risk.
- Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923. doi:10.2165/00003088-200443130-00004 Comprehensive pharmacokinetic and pharmacodynamic review covering enantiomer-specific mechanisms, CYP2D6 polymorphism, and clinical implications of the dual analgesic mechanism.
- Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–285. Landmark study establishing that tramadol’s analgesic activity arises from independent opioid and monoamine reuptake inhibition components.
- Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg. 2017;124(1):44–51. doi:10.1213/ANE.0000000000001683 Review addressing the growing concern of tramadol misuse, its reclassification to Schedule IV, and the clinical significance of CYP2D6 pharmacogenomics.
- Ardakani YH, Rouini MR. Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers. Biopharm Drug Dispos. 2007;28(9):527–533. doi:10.1002/bdd.581 PK study establishing bioavailability (~68%), metabolite profiles, and confirming no clinically significant gender differences in tramadol pharmacokinetics.
- Yun HY, Park SJ, Baek IH, Kwon KI. Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6. Ther Drug Monit. 2019;41(3):378–385. Population PK model quantifying the impact of CYP2D6 polymorphism on tramadol and M1 exposure, supporting pharmacogenomic-guided dosing.
- Tramadol — StatPearls [Internet]. National Library of Medicine. Updated February 20, 2024. ncbi.nlm.nih.gov Comprehensive clinical reference covering indications, mechanism, dosing, CYP interactions, and adverse effects with current FDA labeling updates.